Literature DB >> 16573644

Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury.

J Christofides1, M Bridel, M Egerton, G M Mackay, C M Forrest, N Stoy, L G Darlington, T W Stone.   

Abstract

Following a study of oxidative tryptophan metabolism to kynurenines, we have now analysed the blood of patients with either Huntington's disease or traumatic brain injury for levels of 5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid (5-HIAA) and melatonin. There were no differences in the baseline levels of these compounds between patients and healthy controls. Tryptophan depletion did not reduce 5-HT levels in either the controls or in the patients with Huntington's disease, but it increased 5-HT levels in patients with brain injury and lowered 5-HIAA in the control and Huntington's disease groups. An oral tryptophan load did not modify 5-HT levels in the patients but increased 5-HT in control subjects. The tryptophan load restored 5-HIAA to baseline levels in controls and patients with brain injury, but not in those with Huntington's disease, in whom 5-HIAA remained significantly depressed. Melatonin levels increased on tryptophan loading in all subjects, with levels in patients with brain injury increasing significantly more than in controls. Baseline levels of neopterin and lipid peroxidation products were higher in patients than in controls. It is concluded that both groups of patients exhibit abnormalities in tryptophan metabolism, which may be related to increased inflammatory status and oxidative stress. Interactions between the kynurenine, 5-HT and melatonin pathways should be considered when interpreting changes of tryptophan metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16573644     DOI: 10.1111/j.1471-4159.2006.03807.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

1.  Neuroprotective effect of carvedilol and melatonin on 3-nitropropionic acid-induced neurotoxicity in neuroblastoma.

Authors:  I Tasset; C Espínola; F J Medina; M Feijóo; C Ruiz; E Moreno; M M Gómez; J A Collado; C Muñoz; J Muntané; P Montilla; I Túnez
Journal:  J Physiol Biochem       Date:  2009-09       Impact factor: 4.158

Review 2.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

3.  Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study.

Authors:  N Klepac; M Relja; R Klepac; S Hećimović; T Babić; V Trkulja
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

4.  Delayed onset of the diurnal melatonin rise in patients with Huntington's disease.

Authors:  N Ahmad Aziz; Hanno Pijl; Marijke Frölich; Janny P Schröder-van der Elst; Chris van der Bent; Ferdinand Roelfsema; Raymund A C Roos
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

5.  Metallothionein treatment attenuates microglial activation and expression of neurotoxic quinolinic acid following traumatic brain injury.

Authors:  R S Chung; Y K Leung; C W Butler; Y Chen; E D Eaton; M W Pankhurst; A K West; G J Guillemin
Journal:  Neurotox Res       Date:  2009-03-20       Impact factor: 3.911

Review 6.  The antiapoptotic activity of melatonin in neurodegenerative diseases.

Authors:  Xin Wang
Journal:  CNS Neurosci Ther       Date:  2009-10-10       Impact factor: 5.243

7.  Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin.

Authors:  Caroline M Forrest; Gillian M Mackay; Nicholas Stoy; Trevor W Stone; L Gail Darlington
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

8.  A systems-level "misunderstanding": the plasma metabolome in Huntington's disease.

Authors:  Herminia D Rosas; Gheorghe Doros; Swati Bhasin; Beena Thomas; Sona Gevorkian; Keith Malarick; Wayne Matson; Steven M Hersch
Journal:  Ann Clin Transl Neurol       Date:  2015-05-28       Impact factor: 4.511

9.  Adaptation to experimental jet-lag in R6/2 mice despite circadian dysrhythmia.

Authors:  Nigel I Wood; Catherine J McAllister; Marc Cuesta; Juliet Aungier; Eloise Fraenkel; A Jennifer Morton
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

10.  Kynurenine Pathway in Skin Cells: Implications for UV-Induced Skin Damage.

Authors:  Diba Sheipouri; Nady Braidy; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2012-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.